Vivos Therapeutics seeing positive preliminary metrics following FDA clearance

The company states: “Vivos Therapeutics is pleased to announce that Vivos is seeing positive preliminary metrics following its November 28, 2023 announcement regarding FDA 510(k) clearance of its CARE oral medical devices to treat severe OSA. Vivos reported that during the fourth quarter of 2023, new dentist inquiries to participate in the Vivos Integrated Practice (VIP) program rose 600% over the previous month and the VIP sales pipeline doubled. Signed VIP enrollment contracts increased by 38% sequentially compared to the third quarter of 2023. In addition, average weekly CARE appliance orders increased 26% in the three weeks following the FDA clearance compared to the previous 12-week average for weekly sales for these same devices.” CEO Kirk Huntsman says: “”Since announcing our new FDA clearance for severe OSA, we’ve seen a substantial increase in calls and inquiries from medical doctors, dentists, and patients regarding Vivos’ products. We believe this significant uptick in business development and revenue generating activity since achieving this important milestone highlights our overall value proposition across both the dental and medical communities as a highly effective treatment alternative for OSA patients. With this strong momentum coming into 2024, we expect these higher inquiries and expanded sales pipeline could create opportunities for revenue growth in 2024. Not only are we experiencing considerable growth and interest related to our Vivos CARE products that treat OSA in adults, during the past few weeks we have also seen a 53% increase in sales of our pediatric guided growth and development appliances, which we call Vivos Guides. We expect this trend to continue in the near-term, especially considering the recent success of one of our key strategic dental service organization (DSO) distribution partners, Toothpillow.”